MaxCyte (NASDAQ:MXCT – Get Rating) is one of 39 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its rivals? We will compare MaxCyte to related businesses based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.
This table compares MaxCyte and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for MaxCyte and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Commercial physical research” companies have a potential upside of 49.94%. Given MaxCyte’s rivals higher possible upside, analysts clearly believe MaxCyte has less favorable growth aspects than its rivals.
Insider and Institutional Ownership
65.9% of MaxCyte shares are owned by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 5.4% of MaxCyte shares are owned by insiders. Comparatively, 11.4% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares MaxCyte and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|MaxCyte||$33.89 million||-$19.08 million||-29.12|
|MaxCyte Competitors||$2.80 billion||$101.15 million||12.14|
MaxCyte’s rivals have higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
MaxCyte rivals beat MaxCyte on 7 of the 12 factors compared.
About MaxCyte (Get Rating)
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.